{"id":820367,"date":"2025-03-03T07:08:01","date_gmt":"2025-03-03T12:08:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reiterates-2025-guidance-as-it-reports-fourth-quarter-and-full-year-2024-financial-results\/"},"modified":"2025-03-03T07:08:01","modified_gmt":"2025-03-03T12:08:01","slug":"avadel-pharmaceuticals-reiterates-2025-guidance-as-it-reports-fourth-quarter-and-full-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reiterates-2025-guidance-as-it-reports-fourth-quarter-and-full-year-2024-financial-results\/","title":{"rendered":"Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results"},"content":{"rendered":"
\n

\n — LUMRYZ\u2122 generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8<\/em>\n <\/p>\n

\n — Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million<\/em>\n <\/p>\n

\n — Executing multiple initiatives to accelerate patient demand for LUMRYZ <\/em>\n <\/p>\n

— Patient enrollment is on track in the Phase 3 REVITALYZ\u2122 study to evaluate efficacy and safety of LUMRYZ in Idiopathic Hypersomnia (IH) <\/em><\/p>\n

\n — <\/em>
\n Avadel management to host a conference call today at 8:30 a.m. ET<\/em>\n <\/p>\n

DUBLIN, March 03, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The company has also reiterated the 2025 guidance provided to shareholders on January 8, 2025.<\/p>\n

\u201cBuilding on our progress in 2024, we have launched several initiatives since the start of the year with the primary goal of increasing the number of patients on LUMRYZ,\u201d said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals.\u00a0 \u201cAlthough it is still early in 2025, we are encouraged by the positive trends that are developing and remain laser-focused on making the most of our opportunity in our pursuit of the billion-dollar market potential of LUMRYZ.\u201d\u00a0<\/p>\n

\u201cWe started 2025 with 2,500 patients on LUMRYZ and generated positive cash flow in the fourth quarter of 2024. The evidence for LUMRYZ as an innovative sleep medicine capable of transforming patients\u2019 lives continues to grow. We are investing to accelerate the market adoption of LUMRYZ and are progressing the search for a new leader of our commercial organization with the right experience and capabilities to advance the pace and performance of the LUMRYZ launch and to lead the team through the next phase of significant growth.\u201d<\/p>\n

Avadel has invested in i) expanding its field sales team to reach more physicians, ii) doubling its field reimbursement team to accelerate the pace of patient fulfilment, iii) providing more direct personal support to patients and physicians via an expansion of its nurse team, and iv) adding patient ambassadors to help educate people with narcolepsy.<\/p>\n

Avadel expects to generate $240-$260 million in net product revenue and cash flow of $20 – 40 million during 2025, as the number of patients on LUMRYZ is expected to grow to 3,300 – 3,500. Additionally, Avadel is advancing its pivotal Phase 3 trial for idiopathic hypersomnia (IH), which the company expects will further solidify its leadership in sleep medicine.<\/p>\n

\n Fourth Quarter Highlights and 2025 Guidance: <\/strong>\n <\/p>\n